NK cell therapy for high-risk pediatric soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests whether giving immune cells called NK cells from donated umbilical cord blood can help children and teens with high-risk or returning soft tissue sarcoma. The goal is to see if it is safe and effective when other treatments have been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or younger.
- You must have a high-risk or relapsed/refractory soft tissue sarcoma that has been treated before with surgery, chemo, radiation, or stem cell transplant.
- You should be well enough to have a performance score of at least 50 on a standard scale.
- Your blood counts and organ function must meet certain levels, like enough white blood cells and platelets, and healthy liver and kidneys.
- You must not have active infections, uncontrolled heart problems, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
This trial tests an infusion of activated NK cells (a type of immune cell) to treat sarcomas that are still detectable or not responding well to standard treatment. If you qualify, you may receive this cell therapy while doctors closely check your organ function and heart strength.
This trial tests a new type of immunotherapy using natural killer cells (immune cells that fight cancer) given after a stem cell transplant in children with leukemia or neuroblastoma. The goal is to see if these cells help prevent cancer from coming back and are safe for young patients.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.